Aripiprazole works differently from other antipsychotics. Rather than simply blocking dopamine D2 receptors, it is a partial agonist - it binds the receptor and produces a submaximal response. Where dopamine activity is excessive it reduces it; where activity is low it provides some stimulation. That stabilising action changes both what it does well - the least weight gain and metabolic disturbance of the commonly used antipsychotics - and what goes wrong with it.
Follow the plan your prescriber gave you. This guide contains no doses. Do not stop it abruptly.
The metabolic advantage
Aripiprazole causes considerably less weight gain, less rise in glucose and less disturbance of lipids than olanzapine, quetiapine or risperidone.
Given that people with severe mental illness have a life expectancy substantially shorter than the general population, largely through cardiovascular disease, that is a meaningful advantage rather than a cosmetic one.
It is a common reason for switching someone who has gained substantial weight on another antipsychotic - though switching carries its own relapse risk and is a specialist decision.
See olanzapine and quetiapine.
Monitoring is still required - weight, blood pressure, glucose and lipids before starting, through the first year and then annually.
It lowers prolactin
Most antipsychotics raise prolactin by blocking dopamine's suppressive effect on the pituitary. Aripiprazole's partial agonism means it does the opposite - it lowers prolactin.
That makes it useful for someone troubled by the hormonal effects of another antipsychotic: absent periods, breast enlargement or milk production, sexual dysfunction and reduced bone density.
It is sometimes added at a low dose specifically to correct raised prolactin caused by another drug, which is an elegant solution to a common problem.
See risperidone.
Akathisia
This is aripiprazole's characteristic problem. Akathisia is an intense inner restlessness and inability to keep still - pacing, fidgeting, an unbearable need to move.
It is more common with aripiprazole than with most second-generation antipsychotics, it is genuinely distressing, and it is frequently mistaken for anxiety or agitation - which leads to the dose being increased, making it worse.
Report restlessness or an inability to sit still. It usually appears in the first weeks, it responds to dose reduction, and specific treatments exist.
Other movement effects are less common than with older drugs, but report any involuntary movement of the face or tongue.
Seek urgent help for high fever with muscle rigidity, confusion and sweating - neuroleptic malignant syndrome.
Impulse control disorders
This is the warning fewest people are given. Aripiprazole's dopamine agonist activity can cause pathological gambling, compulsive shopping, binge eating and hypersexuality - the same phenomenon seen with dopamine agonists in Parkinson's disease.
Regulators including the MHRA have issued specific advice about it.
The difficulty is that the person affected does not experience it as a side effect. Savings are lost and relationships end before anyone connects it to a tablet.
Anyone starting aripiprazole should be told about this, and so should the people they live with. If you have noticed new gambling, spending, eating or sexual behaviour since starting, report it - it resolves when the drug is reduced or stopped.
See pramipexole, where the same effect is described.
The long half-life
Aripiprazole and its active metabolite persist for days, so it takes around two weeks to reach steady state after a dose change.
That means dose adjustments should not be made rapidly, and the full effect of an increase is not apparent for a fortnight.
It also means a single missed dose has less immediate consequence than with shorter-acting drugs - though that is not a reason to be casual.
Where it is used
Schizophrenia, mania in bipolar disorder, and as an add-on in treatment-resistant depression, where there is reasonable evidence at low doses.
That last use means a good many people take it without a psychotic illness, and the akathisia and impulse control warnings apply to them exactly as much.
A long-acting depot injection is available, given monthly, for people who find daily tablets difficult.
Other effects
Insomnia, headache, nausea, anxiety and dizziness are common early. It tends to be activating rather than sedating, so it is usually taken in the morning.
It has less effect on the QT interval than most antipsychotics.
Levels are raised by inhibitors of CYP2D6 and CYP3A4 - paroxetine, fluoxetine, clarithromycin - and lowered by carbamazepine.
Stopping
Stopping abruptly risks relapse. Any reduction should be gradual and planned with your team - see why you cannot just stop some medicines.
If you are struggling, Samaritans are free on 116 123, or you can text SHOUT to 85258.
See also Melatonin: Sleep, Children and Jet Lag, and the Conditions section for more on what medicines are prescribed for.